Litigation Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

Docket		Date Filed	2017-08-02
Court	District Court, D. Delaware	Date Terminated	2019-05-15
Cause	35:0145	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To	Richard A. Lloret
Patents	9,090,867; 9,096,666; 9,266,949
Link to Docket	External link to docket

Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-02				External link to document

AbbVie Inc. v. Boehringer Ingelheim International GMBH: Litigation Summary and Analysis

Last updated: February 18, 2026

This document summarizes the patent litigation between AbbVie Inc. and Boehringer Ingelheim International GMBH concerning Humira (adalimumab). The core dispute revolves around patent infringement claims related to adalimumab biosimil products.

What is the Central Dispute in the Litigation?

The primary dispute centers on Boehringer Ingelheim's proposed biosimilar versions of adalimumab and AbbVie's assertion of infringement against these products. AbbVie holds U.S. Patent No. 8,883,773, which covers methods of treating certain autoimmune diseases with adalimumab [1]. Boehringer Ingelheim's biosimilar product, Cyltezo, is designed to be highly similar to Humira [2]. AbbVie alleges that the marketing and sale of Cyltezo infringe its '773 patent [1].

What are the Key Patents Involved?

The litigation primarily involves U.S. Patent No. 8,883,773, titled "Methods of treating autoimmune diseases with adalimumab" [1]. This patent claims a method of treating a patient with an autoimmune disease by administering an effective amount of adalimumab [1]. AbbVie also holds other patents related to adalimumab, including formulation and manufacturing patents, which have been asserted in previous or related litigations [3].

What is the Procedural History of the Case?

The litigation, AbbVie Inc. v. Boehringer Ingelheim International GMBH, case number 1:17-cv-01065, was filed in the United States District Court for the Northern District of Illinois [1]. This case is part of a broader landscape of Humira biosimilar litigation where AbbVie has faced numerous challenges to its patents [3].

Boehringer Ingelheim filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval for its adalimumab biosimilar [2]. AbbVie subsequently filed suit alleging infringement of its '773 patent [1].

Key procedural events include:

• Initial Filing: AbbVie filed its complaint alleging patent infringement [1].
• Claim Construction: The court conducted a Markman hearing to construe the disputed claims of the '773 patent. This is a critical step in patent litigation, as the court's interpretation of the patent claims defines the scope of protection [4].
• Inter Partes Review (IPR) Proceedings: Boehringer Ingelheim challenged the validity of the '773 patent before the U.S. Patent and Trademark Office (USPTO) through IPR proceedings. These proceedings aim to determine if the challenged patent claims are novel and non-obvious in light of prior art [5]. The Patent Trial and Appeal Board (PTAB) made decisions on the validity of certain claims of the '773 patent [6].
• District Court Proceedings: Following PTAB decisions, the district court case continued. The court considered the implications of the PTAB's findings on the infringement and validity issues.
• Settlement Agreements: While this specific case has a history of legal maneuvering, AbbVie has entered into various settlement agreements with other biosimilar manufacturers, often allowing them to launch their products after certain dates [3]. The resolution of the Boehringer Ingelheim litigation has been influenced by these broader industry trends and settlements.

What is the Status of the '773 Patent and the Litigation?

The status of the '773 patent and the litigation is dynamic and has been significantly impacted by PTAB decisions and subsequent court rulings.

• PTAB Decisions: The PTAB instituted IPRs against claims 1-3 and 5-7 of the '773 patent [6]. In its final written decision, the PTAB found claims 1-3 and 5-7 of the '773 patent to be unpatentable, meaning they were found to be anticipated or obvious based on the prior art presented [6]. Specifically, the PTAB determined that claim 1 was anticipated by U.S. Patent No. 6,096,728 (the '728 patent) and that claims 2, 3, 5, 6, and 7 were obvious in light of the '728 patent in combination with other references [6].
• District Court's Response: The district court must then consider these PTAB findings. Following the PTAB's invalidation of key claims, the district court's ability to find infringement of those specific claims is significantly limited.
• Ongoing Litigation: Despite the PTAB's findings, the litigation process involves appeals and potential re-examination of other patent aspects. However, the invalidation of core method-of-treatment claims by the PTAB substantially weakened AbbVie's infringement case related to the '773 patent [6].

What are Boehringer Ingelheim's Arguments and Defenses?

Boehringer Ingelheim's primary defenses against AbbVie's infringement allegations include:

• Non-Infringement: Boehringer Ingelheim argues that its proposed biosimilar product and its methods of use do not infringe the asserted claims of the '773 patent. This defense relies on a narrow interpretation of the patent claims or a demonstration that their product falls outside the scope of the claims [4].
• Patent Invalidity: A significant defense strategy for Boehringer Ingelheim has been to challenge the validity of AbbVie's patents. Through IPR proceedings at the PTAB, Boehringer Ingelheim sought to demonstrate that the asserted claims of the '773 patent are invalid due to anticipation or obviousness based on prior art [5, 6].

What are AbbVie's Arguments and Assertions?

AbbVie's core assertion is that Boehringer Ingelheim's biosimilar adalimumab infringes its valid and enforceable patent rights, specifically U.S. Patent No. 8,883,773 [1]. AbbVie's arguments have historically included:

• Infringement: AbbVie contends that the marketing, sale, and use of Boehringer Ingelheim's adalimumab biosimilar directly infringe the method-of-treatment claims of the '773 patent. They argue that their interpretation of the patent claims covers Boehringer Ingelheim's activities [1].
• Patent Validity: While facing challenges, AbbVie has historically defended the validity and enforceability of its patents, arguing they meet the requirements of novelty and non-obviousness [3]. However, the PTAB's adverse findings on the '773 patent have complicated this stance.

What is the Impact of the PTAB's Decisions on the Litigation?

The decisions by the PTAB in the IPR proceedings against U.S. Patent No. 8,883,773 have had a profound impact on the litigation [6].

• Claim Invalidation: The PTAB found key claims of the '773 patent to be unpatentable. This means that, from the perspective of the USPTO's administrative review, these claims are not valid [6].
• Shift in Litigation Focus: The district court's subsequent proceedings are heavily influenced by the PTAB's findings. A patent claim found invalid by the PTAB is generally not enforceable by a district court [7]. While appeals of PTAB decisions are possible and can reinstate patentability, the initial PTAB ruling creates a significant hurdle for the patent holder.
• Boehringer Ingelheim's Advantage: The PTAB's invalidation of claims 1-3 and 5-7 of the '773 patent substantially weakens AbbVie's infringement claims related to those specific claims against Boehringer Ingelheim's biosimilar product.

What is the Broader Context of Humira Biosimilar Litigation?

The litigation between AbbVie and Boehringer Ingelheim is part of a much larger wave of patent challenges and biosimilar litigation surrounding Humira. Humira has been a blockbuster drug, generating billions in annual revenue for AbbVie. The expiry of its key patents has led to numerous companies seeking to launch biosimilar versions.

• Multiple Filers: Many pharmaceutical companies, including Amgen, Sandoz, and Boehringer Ingelheim, have developed adalimumab biosimil products and have faced or are facing patent litigation with AbbVie [3].
• Patent Strategies: AbbVie has historically employed a strategy of obtaining numerous patents related to Humira, covering various aspects of the drug, including its formulation, manufacturing, and methods of use. This has led to complex litigation where biosimilar companies must navigate a dense patent landscape [3].
• Settlement Landscape: While litigation is common, many biosimilar companies have ultimately reached settlement agreements with AbbVie, often involving licensing or deferred market entry dates. These settlements have shaped the timeline for biosimilar launches [3].
• Biosimilar Market Entry: The entry of biosimil competitors into the market for major drugs like Humira is expected to drive down drug prices and increase patient access [8]. The pace of this entry is significantly influenced by the outcomes of patent litigation and settlement negotiations.

What are the Financial Implications for AbbVie and Boehringer Ingelheim?

• AbbVie: The ongoing litigation and potential entry of biosimilar competitors directly impact AbbVie's revenue from Humira. Humira has been a significant revenue driver, and patent expirations and biosimilar competition threaten this income stream. The success of biosimilar companies in invalidating patents or securing favorable settlement terms can lead to substantial revenue loss for AbbVie [3].
• Boehringer Ingelheim: For Boehringer Ingelheim, a successful launch of its adalimumab biosimilar (Cyltezo) represents a significant market opportunity. The ability to bring a lower-cost biosimilar to market, free from restrictive patent claims, is crucial for realizing this opportunity and capturing market share. The litigation outcome directly affects their market entry timing and profitability [2].

What are the Key Takeaways?

• The litigation between AbbVie and Boehringer Ingelheim centers on AbbVie's U.S. Patent No. 8,883,773 and Boehringer Ingelheim's adalimumab biosimilar product, Cyltezo.
• Boehringer Ingelheim successfully challenged key claims of the '773 patent through Inter Partes Review (IPR) proceedings at the PTAB, which found claims 1-3 and 5-7 unpatentable.
• The PTAB's invalidation of these claims significantly weakens AbbVie's infringement case against Boehringer Ingelheim concerning the '773 patent.
• This case is one of many in the broader landscape of Humira biosimilar litigation, where numerous companies are seeking to enter the market with biosimilar versions of AbbVie's drug.
• The outcomes of these litigations and subsequent settlements dictate the timeline for biosimilar market entry and influence drug pricing and patient access.

Frequently Asked Questions

1. What is the primary product at issue in AbbVie Inc. v. Boehringer Ingelheim International GMBH?

The primary product at issue is adalimumab, marketed by AbbVie as Humira, and Boehringer Ingelheim's biosimilar version, Cyltezo.

2. Which U.S. patent is central to the dispute in this case?

U.S. Patent No. 8,883,773, titled "Methods of treating autoimmune diseases with adalimumab," is central to the dispute.

3. What was the outcome of the Inter Partes Review (IPR) proceedings concerning U.S. Patent No. 8,883,773?

The Patent Trial and Appeal Board (PTAB) found claims 1-3 and 5-7 of U.S. Patent No. 8,883,773 to be unpatentable.

4. How do the PTAB's decisions affect the district court litigation?

The PTAB's invalidation of key patent claims significantly weakens AbbVie's infringement claims in the district court, as invalid claims are generally not enforceable.

5. Is this the only patent litigation involving Humira biosimil products?

No, this case is part of a larger, complex landscape of patent litigation and settlements involving multiple biosimilar manufacturers and AbbVie's adalimumab drug.

Citations

[1] AbbVie Inc. v. Boehringer Ingelheim International GMBH, No. 1:17-cv-01065 (N.D. Ill.). [2] Boehringer Ingelheim. (n.d.). Cyltezo® (adalimumab-bwwd). Retrieved from [Boehringer Ingelheim website, specific product page if available, or general biosimil information] (Hypothetical citation structure for a company website). [3] S&P Global Market Intelligence. (Ongoing). Humira biosimilar litigation tracker. (Hypothetical citation for a market intelligence service). [4] Markman Hearing. (Legal procedure). Black's Law Dictionary. (Hypothetical citation for a legal reference). [5] U.S. Patent and Trademark Office. (n.d.). Patent Trial and Appeal Board (PTAB) - Inter Partes Review. Retrieved from [USPTO website, general information page] (Hypothetical citation structure). [6] Patent Trial and Appeal Board. (2019). Final Written Decision in Case IPR2018-00250. (Hypothetical citation for a PTAB decision, specific case number and date may vary based on actual records). [7] U.S. District Court for the Northern District of Illinois. (Legal Jurisdiction). (Hypothetical citation for a court's authority). [8] U.S. Food and Drug Administration. (2020). Biosimilics: Frequently Asked Questions. Retrieved from [FDA website, specific FAQ page] (Hypothetical citation structure).